Personalized Drug Therapy in Diabetics

The definition of personalized medicine for diabetes (PMFD) is the use of information about the genetic makeup of a person with diabetes to tailor strategies for preventing, detecting, treating, or monitoring their diabetes. The practice of PMFD involves four processes. First is the identification of genes and biomarkers for diabetes as well as for obesity, which is the greatest risk factor for type 2 diabetes. Second, after these predictors of diabetes are identified, is allocation of resources to prevent or detect the diabetes and/or obesity phenotype in high-risk individuals, whose risk is based on their genotype. Third is selection of individualized therapies for affected individuals. The selection process involves deciding which drug to prescribe, what dose of drug to use, and which diet to prescribe. The selection process also accounts for which drug is least likely to cause side effects or toxicity. Fourth is measurement of circulating biomarkers of diabetes to monitor the response to prevention or therapy.

  • Stratified medicine
  • Pharmacogenomics
  • Drug development and usage

Related Conference of Personalized Drug Therapy in Diabetics

February 04-05, 2026

18th International Conference on Gynecology

Rome, Italy
February 25-26, 2026

15th International Conference on Herbal Medicine and Acupuncture

Aix-en-Provence, France
March 09-10, 2026

13th World Machine Learning and Deep learning Conference

Singapore City, Singapore
March 26-27, 2026

12th World Congress on Anesthesia and Critical Care

Amsterdam, Netherlands
April 20-21, 2026

47th International Summit on Human Anatomy & Physiology

Barcelona, Spain
September 14-15, 2026

6th World Medicine Congress

Rome, Italy
October 19-20, 2026

12th World Congress on Medicinal Plants and Marine Drugs

Aix-en-Provence, France

Personalized Drug Therapy in Diabetics Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in